Cash runway is the primary near-term risk — $6.5M is insufficient to fund a 442-patient Phase 3 trial (DUBLIN-4) without a dilutive financing or partnership. Monitor for capital raise announcements (S-3 shelf or private placement) which would be dilutive but necessary to advance the pipeline. The ASCO 2026 OS data is encouraging but early-stage; the stock will likely trade on financing news and DUBLIN-4 initiation timelines rather than quarterly financials.
Price Chart
Executive Summary
BeyondSpring reported Q2 2026 financial results with a net loss from continuing operations of $1.8M, roughly in line with the $1.9M loss in Q2 2025. The company highlighted ASCO 2026 Phase 2 data showing a 58% two-year OS rate for Plinabulin in post-ICI NSCLC and AACR 2026 preclinical ADC combination data. A leadership transition was announced effective July 1, 2026, with Min Qiu appointed CEO to focus on advancing the DUBLIN-4 confirmatory Phase 3 study. Cash burn continues — cash and short-term investments fell to $6.5M from $12.6M at year-end 2025, raising financing risk for a pre-revenue clinical-stage biotech.
Key Financial Metrics
Key Facts
- Net loss from continuing operations was $1.8M for Q2 2026 vs $1.9M in Q2 2025.
- Cash, cash equivalents, and short-term investments were $6.5M as of June 30, 2026, down from $12.6M at December 31, 2025.
- ASCO 2026 Phase 2 data showed 58% two-year OS rate in post-ICI metastatic NSCLC with Plinabulin/docetaxel/pembrolizumab.
- Leadership transition effective July 1, 2026: Min Qiu appointed CEO, Na Li appointed CFO.
- DUBLIN-4 confirmatory Phase 3 study (442 patients) is the lead clinical priority, with regulatory and financing preparations underway.
Financial Impact
Cash burn of ~$6.1M in H1 2026 from continuing operations; $6.5M cash runway is limited for a pre-revenue company planning a 442-patient Phase 3 trial.
Risk Factors
- Cash runway of $6.5M is insufficient to fund DUBLIN-4 Phase 3 trial without additional financing.
- Pre-revenue clinical-stage company with no approved products and no revenue.
- Leadership transition may cause execution risk during a critical development phase.
- Nasdaq continued listing requirement risk noted in forward-looking statements.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001171843-26-005557 |
| Document: f8k_081426.htm | 0001171843-26-005557 |
| Document: 0001171843-26-005557-index-headers.html | 0001171843-26-005557 |
| Document: 0001171843-26-005557-index.html | 0001171843-26-005557 |
| Document: 0001171843-26-005557.txt | 0001171843-26-005557 |
| 8-K Data (Synthetic) | 0001171843-26-005557 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 20d ago | 8-K | $0.6450 $0.5870 | ▼ −8.99% | ▼ −8.01% | $0.4600 (−28.68%) |
Oct 2, 2026 24d ago | 8-K | $0.7860 $0.6155 | ▲ +21.69% | ▲ +22.11% | $0.4600 (+41.48%) |
Sep 29, 2026 27d ago | 8-K | $0.7733 $0.6923 | ▼ −10.47% | ▼ −12.42% | $0.4600 (−40.51%) |
Sep 29, 2026 27d ago | 424B5 | $0.7733 $0.6923 | ▲ +10.47% | ▲ +12.42% | $0.4600 (+40.51%) |
Sep 18, 2026 5w ago | 8-K | $0.7400 $1.12 | ▼ −51.35% | ▼ −52.37% | $0.4600 (+37.84%) |
Sep 3, 2026 7w ago | DEFA14A | $0.6181 $0.7600 | ▲ +22.96% | ▲ +24.17% | $0.4600 (−25.58%) |
Aug 14, 2026 10w ago | 8-K | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4600 (−35.35%) |
Aug 14, 2026 10w ago | Press Release | $0.7115 $0.7092 | ▼ −0.32% | ▲ +0.87% | $0.4600 (−35.35%) |
Jun 4, 2026 20w ago | 8-K | $1.71 $1.65 | ▼ −3.51% | ▼ −0.96% | $0.4600 (−73.10%) |
Jun 2, 2026 20w ago | Press Release | $1.70 $1.72 | ▲ +1.18% | ▲ +4.14% | $0.4600 (−72.94%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers